Login
$MEDP
$673.79 -$2.98 (0.44%) Close

$MEDP 3 SEC Filings

Filed On Filing
04 Jun 2026 Form 3: Hansman Brad W., Exec. VP, Operations

Holds 697 shares of Common Stock

03 Jul 2024 Form 3: Zander Dani S., Director

No securities owned

18 Jan 2023 Form 3: Gwadry-Sridhar Femida H., Director

No securities owned

10 Aug 2021 Form 3: Brady Kevin M., CFO & Treasurer

Holds 5,000 shares of Common Stock

28 Oct 2019 Form 3: King Tom C, Director

No securities owned

21 May 2019 Form 3: Keating Ashley M., Director

No securities owned

15 Aug 2018 Form 3: McCarthy Cornelius P. Iii, Director

No securities owned

15 Aug 2018 Form 3: Davenport Fred B Jr, Director

Holds 1,500 shares of Common Stock

22 Jun 2017 Form 3: Medpace Limited Partnership, 10% owner and 1 other

Holds 22,999,997 shares of Common Stock

03 Nov 2016 Form 3: Brown Bruce, Director

No securities owned

16 Aug 2016 Form 3: Medpace Investors, Llc, 10% owner

Holds 9,210,118 shares of Common Stock

10 Aug 2016 Form 3: Cinven Capital Management (V) General Partner Ltd, 10% owner and 4 others

Holds 22,999,997 shares of Common Stock

10 Aug 2016 Form 3: Fifth Cinven Fund (No. 1) Limited Partnership, 10% owner and 5 others

Holds 22,999,997 shares of Common Stock

10 Aug 2016 Form 3: Troendle August J., Director

Holds 351,851 shares of Common Stock

10 Aug 2016 Form 3: Rajagopalan Supraj R, Director

No securities owned

10 Aug 2016 Form 3: Norton Matthew Richard, Director

No securities owned

10 Aug 2016 Form 3: Leslie Alexander F S, Director

No securities owned

10 Aug 2016 Form 3: Kraft Robert O., Director

No securities owned

10 Aug 2016 Form 3: Geiger Jesse J, CFO & COO, Lab Operations
10 Aug 2016 Form 3: Ewald Stephen P, General Counsel & Corp. Secy.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support